OvaScience CFO Steps Down Effective Immediately, Replacement Named

OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth

Christophe Couturier Named Chief Financial Officer

— Karen Long Named Executive Vice President, Clinical and Regulatory Affairs and Quality Assurance —

James Luterman, Ph.D. Promoted to Executive Vice President, Research and Development

WALTHAM, Mass.--()--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced changes to its senior management team, reflecting the Company’s continued evolution and global growth. Christophe Couturier has been named Chief Financial Officer, effective immediately. He succeeds Jeff Young, who is pursuing other opportunities and will be leaving OvaScience after a transition period. Karen Long joins the Company as Executive Senior Vice President, Clinical and Regulatory Affairs and Quality Assurance and James Luterman, Ph.D., OvaScience’s Senior Vice President, Research and Development, has been promoted to Executive Vice President, Research and Development. All will report directly to Harald Stock, Ph.D., President and Chief Executive Officer of OvaScience.

“We welcome Christophe to OvaScience in this critical position for our path forward. His extensive experience working in a range of financial roles for global life science companies will be indispensable as we continue to commercialize our novel treatments in multiple international markets and will strengthen the already talented financial team we have in place,” said Harald Stock, Ph.D., President and Chief Executive Officer of OvaScience. “We thank Jeff for his numerous contributions to OvaScience and wish him the best in his future endeavors.”

Christophe Couturier has nearly 20 years of experience with a proven record in management, finance and strategic planning across multiple geographies. Most recently, he served as Senior Vice President and General Manager at Merck KGaA (Darmstadt, Germany), where he led the Merck KGaA/Pfizer Global Immuno-Oncology Alliance. Previously, he worked in a series of roles at MilliporeSigma, including serving as Senior Vice President of the Merck KGaA/Sigma-Aldrich Integration Program, Vice President of Corporate Financial Planning and Analysis and Vice President of Finance Operations for the company’s Bioprocess and BioScience divisions. Prior to joining Merck KGaA in 2004, Christophe worked as an Associate Partner at IBM Business Consulting Services, as a Finance Director at Lloyds Pharmacy and as a Head of Finance for Novartis, with positions in Hungary, Norway, Turkey and Switzerland. He holds an M.B.A. from ESSEC Business School in France.

Karen Long joins OvaScience from Danaher, Leica Biosystems, where she was Vice President, Regulatory Affairs and Quality Assurance and oversaw the development of the company’s quality management systems, regulatory, clinical research and compliance programs. Karen has more than 20 years of industry experience, including various senior positions in regulatory affairs at Abbott, Roche Molecular Systems, Inc., Calypte Biomedical Corporation and Baxter Healthcare Therapeutics. She holds a B.S. in Biochemistry and Medical Technology from the University of Illinois.

James Luterman, Ph.D. has been with OvaScience since January 2014 and brings over 20 years of industry experience to the Company. Most recently he served as Senior Vice President, Research and Development at OvaScience. Prior to OvaScience, Dr. Luterman held various positions at Shire Human Genetic Therapies. He also worked at Biogen and Decision Resources Group. He holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine.

Dr. Stock added, “Karen’s background in navigating clinical and regulatory affairs for international healthcare companies will provide critical insight as we seek to refine our regulatory strategies in key international markets. Further, Jim’s scientific expertise and commitment to building a robust body of preclinical data have allowed us to ensure the development of our pipeline treatments – OvaTure and OvaPrime – are on track. I’m eager to work with Christophe, Karen and Jim on my executive team.”

About OvaScience
OvaScience (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience has commenced a non-commercial preceptorship training program with the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit www.ovascience.com and www.augmenttreatment.com and connect with us on Twitter and Facebook.

Forward-Looking Statements
This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment, OvaPrime treatment and OvaTure treatment, including statements relating to the status of our treatment programs and contributions by members of the Company’s executive team. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to provide or continue providing the AUGMENT treatment or OvaPrime treatment, or to delay providing such treatments based on clinical efficacy, safety or commercial, logistic, regulatory or other reasons; the science underlying our treatments (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.



Media and Investor Contact:
Jennifer Viera, 617-420-8748

Back to news